Biology and management of therapy-related acute promyelocytic leukemia

Current Opinion in Oncology

Volumn 25, Issue 6, 2013, Pages 695-700

  Lo Coco, Francesco ^a,b   Hasan, Syed K ^a,b   Montesinos, Pau ^c   Sanz, Miguel A ^c  

^a UNIVERSITY OF ROME TOR VERGATA   (Italy)

^b IRCCS FONDAZIONE SANTA LUCIA   (Italy)

^c HOSPITAL UNIVERSITARIO LA FE   (Spain)

Author keywords

acute promyelocytic leukemia; arsenic trioxide; retinoic acid; therapy related

Indexed keywords

ARSENIC TRIOXIDE; AZATHIOPRINE; BETA INTERFERON; CYTOTOXIC AGENT; DNA; DNA BINDING PROTEIN; DNA TOPOISOMERASE; DNA TOPOISOMERASE (ATP HYDROLYSING); DOUBLE STRANDED DNA; IMMUNOSUPPRESSIVE AGENT; MITOXANTRONE; NUCLEOTIDE; RETINOIC ACID; STEROID; TRANSCRIPTION FACTOR;

ADAPTATION; AUTOIMMUNE DISEASE; BIOLOGY; BREAST CANCER; CANCER CHEMOTHERAPY; CANCER COMBINATION CHEMOTHERAPY; CANCER PATIENT; CANCER RISK; CELL CYCLE CHECKPOINT; CELL DEATH; CHROMOSOME; CHROMOSOME TRANSLOCATION; DNA DAMAGE; DNA END JOINING REPAIR; DNA HELIX; DNA REPAIR; DNA REPLICATION; DNA STRAND BREAKAGE; EARLY DIAGNOSIS; ENTERITIS; FOLLOW UP; HOMOLOGOUS RECOMBINATION; HUMAN; LEUKEMOGENESIS; MANAGEMENT; MOLECULAR PATHOLOGY; MULTIPLE SCLEROSIS; PATIENT MONITORING; PREVALENCE; PRIMARY TUMOR; PRIORITY JOURNAL; PROMYELOCYTIC LEUKEMIA; RETROSPECTIVE STUDY; REVIEW; RHEUMATOID ARTHRITIS; RISK FACTOR; SISTER CHROMATID EXCHANGE; THERAPY RELATED ACUTE PROMYELOCYTIC LEUKEMIA; TREATMENT OUTCOME; TUMOR GROWTH;

ADULT; ANTINEOPLASTIC AGENTS; ARSENICALS; EARLY DIAGNOSIS; FEMALE; HUMANS; LEUKEMIA, PROMYELOCYTIC, ACUTE; MALE; MIDDLE AGED; NEOPLASMS, SECOND PRIMARY; OXIDES; RETROSPECTIVE STUDIES; RISK FACTORS; TRETINOIN;

EID: 84885420409     PISSN: 10408746     EISSN: 1531703X     Source Type: Journal    
DOI: 10.1097/CCO.0000000000000013     Document Type: Review

References (28)

1. Vardiman JW, Thiele J, Arber DA, et al. The 2008 revision of the World Health Organization (WHO) classification of myeloid neoplasms and acute leukemia: rationale and important changes. Blood 2009; 114:937-951.
2. Joannides M, Mays AN, Mistry AR, et al. Molecularpathogenesis of secondary acute promyelocytic leukemia. Mediterr J Hematol Infect Dis 2011; 3:e2011045.
3. Ramadan SM, Fouad TM, Summa V, et al. Acute myeloid leukemia developing in patients with autoimmune diseases. Haematologica 2012; 97:805-817.
4. Beaumont M, Sanz M, Carli PM, et al. Therapy related acute promyelocytic leukemia. J Clin Oncol 2003; 21:2123-2137.
5. Ammatuna E, Montesinos P, Hasan SK, et al. Presenting features and treatment outcome of acute promyelocytic leukemia arising after multiple sclerosis. Haematologica 2011; 96:621-625.
6. Dayyani F, Kantarjian H, O'Brien S, et al. Outcome of therapy-related acute promyelocytic leukaemia with or without arsenic trioxide as a component of frontline therapy. Cancer 2011; 117:110-115.
7. Mays AN, Osheroff N, Xiao Y, et al. Evidence for direct involvement of epirubicin in the formation of chromosomal translocations in t(15;17) therapy-related acute promyelocytic leukemia. Blood 2010; 115:326-330.
8. Hasan SK, Mays AN, Ottone T, et al. Molecular analysis of t(15;17) genomic breakpoints in secondary acute promyelocytic leukemia arising after treatment of multiple sclerosis. Blood 2008; 112:3383-3390.
9. Mistry AR, Felix CA, Whitmarsh RJ, et al. DNA topoisomerase II in therapy-related acute promyelocytic leukemia. N Engl J Med 2005; 352:1529-1538.
10. Cowell IG, Austin CA. Mechanism of generation of therapy related leukaemia in response to antitopoisomerase II agents. Int J Environ Res Public Health 2012; 9:2075-2091.
11. Hasan SK, Ottone T, Schlenk R, et al. Analysis of t(15;17)(q22;21) chromosomal breakpoint sequences in therapy-related versus de novo acute pro-myelocytic leukemia: association of DNA breaks with specific DNA motifs at PML and RARA loci. Genes Chromosomes Cancer 2010; 49:726-732.
12. de Thé H, Chen Z. Acute promyelocytic leukaemia: novel insights into the mechanisms of cure. Nat Rev Cancer 2010; 10:775-783.
13. Nasr R, Guillemin MC, Ferhi O, et al. Eradication of acute promyelocytic leukemia-initiating cells through PML-RARA degradation. Nat Med 2008; 14:1333-1342.
14. Deweese JE, Osheroff N. The DNA cleavage reaction of topoisomerase II: wolf in sheep's clothing. Nucleic Acids Res 2009; 37:738-748.
15. Nitiss JL. Targeting DNA topoisomerase II in cancer chemotherapy. Nat Rev Cancer 2009; 9:338-350.
16. Felix CA, Kolaris CP, Osheroff N. Topoisomease II and the etiology of chromosomal translocations. DNA Repair 2006; 5:1093-1108.
17. de Campos-Nebel M, Larripa I, Gonzalez-Cid M. Topoisomerase II-mediated DNA damage is differently repaired during the cell cycle by nonhomologous end joining and homologous recombination. PLoS One 2010; 5:e12541.
18. Ottone T, Hasan SK, Montefusco E, et al. Identification of a 'Hotspot' DNA Region in the AML1 gene targeted by mitoxantrone in therapy-related acute myeloid leukemia with t(16;21) translocation. Genes Chromosomes Cancer 2009; 48:213-221.
19. Hasan SK, Buttari F, Ottone T, et al. Risk of acute promyelocytic leukemia in multiple sclerosis: a study on coding variants of DNA repair genes. Neurology 2011; 76:1059-1065.
20. Pulsoni A, Pagano L, Lo Coco F, et al. Clinicobiological features and outcome of acute promyelocytic leukemia occurring as a second tumor: the GIMEMA experience. Blood 2002; 100:1972-1976.
21. Elliott MA, Letendre L, Tefferi A, et al. Therapy-related acute promyelocytic leukemia: observations relating to APL pathogenesis and therapy. Eur J Haematol 2012; 88:237-243.
22. Yin CC, Glassman AB, Lin P, et al. Morphologic, cytogenetic, and molecular abnormalities in therapy-related acute promyelocytic leukemia. Am J Clin Pathol 2005; 123:840-848.
23. Duffield AS, Aoki J, Levis M, et al. Clinical and pathologic features of secondary acute promyelocytic leukemia. Am J Clin Pathol 2012; 137:395-402.
24. Ottone T, Cicconi L, Hasan SK, et al. Comparative molecular analysis of therapy-related and de novo acute promyelocytic leukemia. Leuk Res 2012; 36:474-478.
25. Chan A, Lo Coco F. Mitoxantrone-related acute leukemia in MS: an open or closed book? Neurology 2013; 80:1529-1533.
26. Sanz MA, Grimwade D, Tallman MS, et al. Management of acute promyelo-cytic leukemia: recommendations from an expert panel on behalf of the European LeukemiaNet. Blood 2009; 113:1875-1891.
27. Rashidi A, Fisher SI. Therapy-related acute promyelocytic leukemia: a systematic review. Med Oncol 2013; 30:625-634.
28. Lo-Coco F, Avvisati G, Vignetti M, et al. All-trans retinoic acid and arsenic trioxide for acute promyelocytic leukemia. N Engl J Med 2013; 369:111-121.